Imbed Biosciences, manufacturers of MicroLyte Ag VET®, a one-of-a-kind, Food and Drug Administration (FDA) cleared wound dressing that promotes healing and fights infection in wounds and burns, announces a new relationship with MWI Animal Health for distribution of MicroLyte Ag VET into veterinarian practices and clinics, animal hospitals and academic research facilities across the U.S. MWI is a leading distributor of animal health products and services.
Manufactured at Imbed Biosciences’ Madison, Wisconsin ISO 13485 certified facility, MicroLyte Ag VET was previously only available directly through Imbed, but significant growth and demand for the product from the veterinary community led to the relationship with MWI.
“As interest in the product is very positive and growing, we are excited that this distribution agreement with MWI Animal Health allows our recently launched veterinary division to make MicroLyte Ag VET immediately available to meet the wound treatment needs of veterinarians and veterinary clinics across the country,” said Ankit Agarwal, Chief Executive Officer of Imbed Biosciences.
Unlike traditional antimicrobial dressings, Imbed’s ultrathin Microfilm™ technology enables MicroLyte Ag VET to conform intimately to the tissue of a wound bed. Demonstrated in vitro to be effective against several resistant microorganisms, including Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE), MicroLyte Ag VET helps wounds heal with a specially designed layer of antimicrobial silver that doesn’t inhibit healing. New cells can form on top of the product, which completely absorbs into the body.
MicroLyte Ag VET is simple to use. Once removed from its peelable foil pouch, the matrix can be placed on a moist, debrided wound. The matrix will immediately contour to the wound bed and provide active antimicrobial silver in the wound for up to three days. The wound and matrix can then be covered with a second dressing for moisture management.
“The ultrathin form factor of MicroLyte Ag VET is key to the success of this product. It conforms very tightly to the wound bed and exerts antimicrobial action on microorganisms hiding in the ‘nooks and crannies’ of the wound,” said Agarwal.
MicroLyte Ag VET is not harmful to periwound skin because of its conformal nature and because it contains a much lower amount of silver than other traditional silver-based dressings that sit above the wound bed. Most of the silver released by traditional dressings gets inactivated in the wound fluid and leads to tissue toxicity and staining.
Because MicroLyte Ag VET is fully resorbable, there is no need to actively remove the product from the wound bed prior to reapplication. If removal is necessary, MicroLyte Ag VET can be removed by gentle irrigation with sterile saline. The product can also be trimmed according to wound size before or after placement in the wound.
MicroLyte Ag VET is currently available in the U.S. To learn more about MicroLyte Ag VET visit www.microlyteagvet.com.
About Imbed Biosciences
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastrointestinal defect and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® Matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, Wis., and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.microlytematrix.com or www.microlyteagvet.com.